CG Oncology Ratios (2023-2026) | CGON

Ratios Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
Gross Margin (Quarter) 100.00%100.00%100.00%5.34%-32.21%-173.50%
EBT Margin (Quarter) -4,611.34%-131,322.22%-1,655,100.00%-46,903.40%-154,904.50%-412,993.02%-6,987.72%-234,169.23%-14,071.67%-1,785.57%-40,904.25%
EBIT Margin (Quarter) -5,010.82%-156,033.33%-1,935,500.00%-4,247.45%-23,290.99%-65,802.33%-8,344.08%-81,161.54%-3,068.97%-2,097.33%-6,130.10%
EBITDA Margin (Quarter) -5,010.82%-156,033.33%-1,935,500.00%-4,247.45%-23,290.99%-65,802.33%-8,344.08%-81,161.54%-3,068.97%-2,097.33%-6,130.10%
Operating Margin (Quarter) -5,010.82%-156,033.33%-1,935,500.00%-4,247.45%-23,290.99%-65,802.33%-8,344.08%-81,161.54%-3,068.97%-2,097.33%-6,130.10%
Net Margin (Quarter) -6,392.27%-194,600.00%-2,249,000.00%-3,200.76%-17,028.83%-47,453.49%-6,973.25%-234,169.23%-14,071.67%-1,785.57%-40,904.25%
FCF Margin (Quarter) -4,116.49%-136,244.44%-1,464,500.00%-4,919.47%-14,535.14%-37,018.60%-4,576.97%-56,332.69%-2,338.60%-1,559.30%-5,281.99%
Efficiency
Inventory Average (Quarter) 1.53M1.53M
Assets Average (Quarter) 389.20M571.72M558.40M653.63M741.49M714.81M715.68M760.75M963.43M
Asset Utilization Ratio (Quarter) 0.000.000.000.000.000.000.000.010.01
Leverage & Solvency
Interest Coverage Ratio (Quarter) -35.87-273.91-238.02-0.10-0.17-0.18-634.15-0.48-0.46-0.27-237.56-0.17
Debt Ratio (Quarter) 0.000.000.00
Times Interest Earned (Quarter) -35.87-273.91-238.02-0.10-0.17-0.18-634.15-0.48-0.46-0.27-237.56-0.17
Valuation
Enterprise Value (Quarter) -187.67M-566.51M-552.88M-540.71M-742.00M-688.43M-661.05M-680.26M-742.15M-1076.24M
Return Ratios
Return on Sales (Quarter) -0.46%-13.13%-165.51%-4.69%-15.49%-41.30%-0.70%-23.42%-8.70%-1.41%-0.18%-4.09%
Return on Capital Employed (Quarter) -17.98%-14.60%-17.68%-18.14%-18.70%-22.98%-26.29%-26.14%-23.16%
Return on Assets (Quarter) -0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%